Genzyme has announced plans to launch three products in India, reported Indian Express Finance. The company’s two products, an adhesion barrier that reduces complications after post-abdominal and gynaecological surgery, and drug for cartilage repair will be launched by next year. The third drug is indicated for the treatment of osteoarthritis of joints.
The drugs are filed with DCGI, and the company expects to get approval soon.
Sandeep Sahney, managing director of Genzyme India, said to Indian Express Finance: “Of our total existing global product portfolio of 17, we have already brought eight products to India. We intend to bring our entire range of products to the country within the next three years. For the year ahead, we plan to bring two of our products to India and are considering the commercialisation of a third drug as well.”